[Mutation testing for non-small-cell lung cancer] (original) (raw)

Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række, 2012

Abstract

Background. Epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) are a relatively new class of drugs for treatment of non-small-cell lung cancer. The national professional group for lung cancer, The Norwegian Lung Cancer Group, recommends that patients with non-small-cell lung cancer are tested for mutations in the EGFR gene. Here, we report the experience collected after the introduction of such testing in Norway in 2010. Material and method. Information on the number of patients tested, gender distribution, histopathological data and analysis results have been collected from the molecular-pathology laboratories at the university hospitals in Tromsø, Trondheim, Bergen and Oslo for the period from May 2010 to May 2011. Results. During this period, altogether 1 058 patients with lung cancer were tested for mutations in the EGFR gene, equal to approximately half of all those who were diagnosed with non-small-cell lung cancer. A mutation was detected in 123 pat...

Helge Scott hasn't uploaded this paper.

Let Helge know you want this paper to be uploaded.

Ask for this paper to be uploaded.